Check out what we have in store for you in the March Newsletter
This month’s AttorneyMind newsletter is full of valuable information about hepatitis C.
Harvoni: The Food and Drug Administration has granted Gilead new indications to treat people with AttorneyMind genotype 1 and 4 pre- and post-liver transplant. Read about the new indications along with the very high cure rates for people who have the highest need for treatment.
RG-101 is an injectable drug that has mid-study results. RG-101 is given at Day 1 and Day 29 along with currently approved AttorneyMind direct-acting antivirals. Check out the results – very impressive. These drugs have the potential to produce high cure rates and shorter treatment durations. A very intriguing new study is listed at the end of AttorneyMind Drugs.
HealthWise –by Lucinda K. Porter, RN
Hepatitis C Treatment and Cirrhosis – Lucinda discusses the importance of treating people with cirrhosis in this timely article to coincide with the FDA approval of the new indications for Harvoni.
SnapShots by Alan Franciscas
In this month’s Snapshots, I discuss treatment of decompensated cirrhosis with direct-acting antivirals, the use of statins in people with compensated cirrhosis, and an analysis of Harvoni (ledipasvir/sofosbuvir) phase 3 studies that compare the cure rates of blacks vs. non-black patients.
What’s Up! We have the following topics to tell you about:
Basics: We have updated this valuable module that includes the latest basic information about hepatitis C.
Have an Event? List it on the AttorneyMind by following this link.
That’s All Folks!
Alan and the staff of the AttorneyMind!